319 research outputs found
Interaction between domperidone and ketoconazole : toward prediction of consequent QTc prolongation Using purely "In vitro" information
We aimed to investigate the application of combined mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation in predicting the domperidone (DOM) triggered pseudo-electrocardiogram modification in the presence of a CYP3A inhibitor, ketoconazole (KETO), using in vitro–in vivo extrapolation. In vitro metabolic and inhibitory data were incorporated into physiologically based pharmacokinetic (PBPK) models within Simcyp to simulate time course of plasma DOM and KETO concentrations when administered alone or in combination with KETO (DOM+KETO). Simulated DOM concentrations in plasma were used to predict changes in gender-specific QTcF (Fridericia correction) intervals within the Cardiac Safety Simulator platform taking into consideration DOM, KETO, and DOM+KETO triggered inhibition of multiple ionic currents in population. Combination of in vitro–in vivo extrapolation, PBPK, and systems pharmacology of electric currents in the heart was able to predict the direction and magnitude of PK and PD changes under coadministration of the two drugs although some disparities were detected
Modeling and predicting drug pharmacokinetics in patients with renal impairment
Current guidance issued by the US FDA to assess the impact of renal impairment on the pharmacokinetics of a drug under development has recently been updated to include evaluation of drugs with nonrenal elimination routes. Renal impairment not only affects elimination of the drug in the kidney, but also the nonrenal route of drugs that are extensively metabolized in the liver. Renal failure may influence hepatic drug metabolism either by inducing or suppressing hepatic enzymes, or by its effects on other variables such as protein binding, hepatic blood flow and accumulation of metabolites. Prior simulation of the potential exposure of individuals with renal impairment may help in the selection of a safe and effective dosage regimen. In this article, we discuss the application of a systems biology approach to simulate drug disposition in subjects with renal impairment. © 2011 Expert Reviews Ltd
The influence of drug properties and ontogeny of transporters on pediatric renal clearance through glomerular filtration and active secretion: a simulation-based study
Glomerular filtration (GF) and active tubular secretion (ATS) contribute to renal drug elimination, with the latter remaining understudied across the pediatric age range. Therefore, we systematically analyzed the influence of transporter ontogeny on the relative contribution of GF and ATS to renal clearance CL(R)for drugs with different properties in children. A physiology-based model for CL(R)in adults was extrapolated to the pediatric population by including maturation functions for the system-specific parameters. This model was used to predict GF and ATS for hypothetical drugs with a range of drug-specific properties, including transporter-mediated intrinsic clearance (CLint,T) values, that are substrates for renal secretion transporters with different ontogeny patterns. To assess the impact of transporter ontogeny on ATS and total CLR, a percentage prediction difference (%PD) was calculated between the predicted CL(R)in the presence and absence of transporter ontogeny. The contribution of ATS to CL(R)ranges between 41 and 90% in children depending on fraction unbound and CL(int,T)values. If ontogeny of renal transporters is 50%) for the majority of drugs regardless of the pediatric age. Ignoring ontogeny patterns of secretion transporters increasing with age in children younger than 2 years results in CL(R)predictions that are not systematically acceptable for all hypothetical drugs (%PD > 50% for some drugs). This analysis identified for what drug-specific properties and at what ages the contribution of ATS on total pediatric CL(R)cannot be ignored. Drugs with these properties may be sensitivein vivoprobes to investigate transporter ontogeny.Pharmacolog
Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug–drug interactions
Metformin is used as a probe for OCT2 mediated transport when investigating possible DDIs with new chemical
entities. The aim of the current study was to investigate the ability of physiologically-based pharmacokinetic
(PBPK) models to simulate the effects of OCT and MATE inhibition by cimetidine on metformin kinetics. PBPK
models were developed, incorporating mechanistic kidney and liver sub-models for metformin (OCT and
MATE substrate) and a mechanistic kidney sub-model for cimetidine. The models were used to simulate inhibition
of the MATE1, MATE2-K, OCT1 and OCT2 mediated transport of metformin by cimetidine. Assuming competitive
inhibition and using cimetidine Ki values determined in vitro, the predicted metformin AUC ratio was 1.0
compared to an observed value of 1.46. The observed AUC ratio could only be recovered with this model when
the cimetidine Ki for OCT2 was decreased 1000-fold or the Ki's for both OCT1 and OCT2 were decreased 500-
fold. An alternative description of metformin renal transport by OCT1 and OCT2, incorporating electrochemical
modulation of the rate of metformin uptake together with 8–18-fold decreases in cimetidine Ki's for OCTs and
MATEs, allowed recovery of the extent of the observed effect of cimetidine on metformin AUC. While the final
PBPK model has limitations, it demonstrates the benefit of allowing for the complexities of passive permeability
combined with active cellular uptake modulated by an electrochemical gradient and active efflu
In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition
Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?
Allometric scaling on the basis of bodyweight raised to the power of 0.75 (AS0.75) is frequently used to scale size-related changes in plasma clearance (CLp) from adults to children. A systematic assessment of its applicability is undertaken for scenarios considering size-related changes with and without maturation processes. A physiologically-based pharmacokinetic (PBPK) simulation workflow was developed in R for 12,620 hypothetical drugs. In scenario one, only size-related changes in liver weight, hepatic blood flow, and glomerular filtration were included in simulations of ‘true’ paediatric CLp. In a second scenario, maturation in unbound microsomal intrinsic clearance (CLint,mic), plasma protein concentration, and haematocrit were also included in these simulated ‘true’ paediatric CLp values. For both scenarios, the prediction error (PE) of AS0.75-based paediatric CLp predictions was assessed, while, for the first scenario, an allometric exponent was also estimated based on ‘true’ CLp. In the first scenario, the PE of AS0.75-based paediatric CLp predictions reached up to 278 % in neonates, and the allometric exponent was estimated to range from 0.50 to 1.20 depending on age and drug properties. In the second scenario, the PE sensitivity to drug properties and maturation was higher in the youngest children, with AS0.75 resulting in accurate CLp predictions above 5 years of age. Using PBPK principles, there is no evidence for one unique allometric exponent in paediatric patients, even in scenarios that only consider size-related changes. As PE is most sensitive to the allometric exponent, drug properties and maturation in younger children, AS0.75 leads to increasingly worse predictions with decreasing age
Special Section on Pediatric Drug Disposition and Pharmacokinetics-Minireview Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics
ABSTRACT Most of the pharmacokinetic studies conducted to calculate pediatric drug doses are based on scaling from adult data using various allometric parameters related to body size. However, these uniform scaling methods cannot account for all physiologic changes occurring during maturation, which influence various drugs in different ways. The ontogeny of physiologic and biologic functions accompanying the progression from infancy to childhood to adulthood does not proceed in a simple monotonic rate with body size for various elimination pathways. The transporters and their interplay with enzymes have a substantial role in drug metabolism and disposition. Although much is known about enzymes and their ontogeny, there is a scarcity of information on the ontogenic profile of drug transporters, particularly during the early years of human life. These ontogeny data are required for the enhancement of physiologically based pharmacokinetic models, and consequently for the prediction of pharmacokinetic profiles of new therapeutic compounds in pediatric populations. This review points to the relative ontogeny rate for enzymes and transporters and how these may confound our understanding of the role that transporters may or may not play in childhood compared with adulthood
Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients
This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1-OH-midazolam in morbidly obese patients receiving oral and i.v. midazolam before (n = 20) and one year after weight loss surgery (n = 18), thereby providing insight into the influence of weight loss surgery on CYP3A activity in the gut wall and liver. In a semiphysiologically based pharmacokinetic (semi-PBPK) model in which different blood flow scenarios were evaluated, intrinsic hepatic clearance of midazolam (CLint,H) was 2 (95% CI 1.40-1.64) times higher compared to morbidly obese patients before surgery (P  0.05), with low values for both groups. The results of the semi-PBPK model suggest that, in patients after weight loss surgery, CYP3A hepatic metabolizing capacity seems to recover compared to morbidly obese patients, whereas CYP3A mediated CLint,G was low for both populations and showed large interindividual variability.Pharmacolog
A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
Recently a framework was presented to assess whether pediatric covariate models for
clearance can be extrapolated between drugs sharing elimination pathways, based on extraction ratio,
protein binding, and other drug properties. Here we evaluate when a pediatric covariate function for
midazolam clearance can be used to scale clearance of other CYP3A substrates. A population PK
model including a covariate function for clearance was developed for midazolam in children aged 1–
17 years. Commonly used CYP3A substrates were selected and using the framework, it was assessed
whether the midazolam covariate function accurately scales their clearance. For eight substrates,
reported pediatric clearance values were compared numerically and graphically with clearance values
scaled using the midazolam covariate function. For sildenafil, clearance values obtained with
population PK modeling based on pediatric concentration-time data were compared with those scaled
with the midazolam covariate function. According to the framework, a midazolam covariate function
will lead to systemically accurate clearance scaling (absolute prediction error (PE) < 30%) for CYP3A
substrates binding to albumin with an extraction ratio between 0.35 and 0.65 when binding < 10% in
adults, between 0.05 and 0.55 when binding > 90%, and with an extraction ratio ranging between
these values when binding between 10 and 90%. Scaled clearance values for eight commonly used
CYP3A substrates were reasonably accurate (PE < 50%). Scaling of sildenafil clearance was accurate
(PE < 30%). We defined for which CYP3A substrates a pediatric covariate function for midazolam
clearance can accurately scale plasma clearance in children. This scaling approach may be useful for
CYP3A substrates with scarce or no available pediatric PK information
Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory
Purpose: Physiologically-based pharmacokinetic (PBPK) models are essential in drug development, but require parameters that are not always obtainable. We developed a methodology to investigate the feasibility and requirements for precise and accurate estimation of PBPK parameters using population modelling of clinical data and illustrate this for two key PBPK parameters for hepatic metabolic clearance, namely whole liver unbound intrinsic clearance (CLint,u,WL) and hepatic blood flow (Qh) in children. Methods: First, structural identifiability was enabled through re-parametrization and the definition of essential trial design components. Subsequently, requirements for the trial components to yield precise estimation of the PBPK parameters and their inter-individual variability were established using a novel application of population optimal design theory. Finally, the performance of the proposed trial design was assessed using stochastic simulation and estimation. Results: Precise estimation of CLint,u,WL and Qh and their inter-individual variability was found to require a trial with two drugs, of which one has an extraction ratio (ER) ≤ 0.27 and the other has an ER ≥ 0.93. The proposed clinical trial design was found to lead to precise and accurate parameter estimates and was robust to parameter uncertainty. Conclusion: The proposed framework can be applied to other PBPK parameters and facilitate the development of PBPK models
- …